Research ExplorerPublicationsAutoantibodies targeting G protein-coupled receptors: An evo...

Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Standard

Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. / Cabral-Marques, Otávio; Moll, Guido; Catar, Rusan; Preuß, Beate; Bankamp, Lukas; Pecher, Ann-Christin; Henes, Joerg; Klein, Reinhild; Kamalanathan, A S; Akbarzadeh, Reza; van Oostveen, Wieke; Hohberger, Bettina; Endres, Matthias; Koolmoes, Bryan; Levarht, Nivine; Postma, Rudmer; van Duinen, Vincent; van Zonneveld, Anton Jan; de Vries-Bouwstra, Jeska; Fehres, Cynthia; Tran, Florian; do Vale, Fernando Yuri Nery; da Silva Souza, Kamilla Batista; Filgueiras, Igor Salerno; Schimke, Lena F; Baiocchi, Gabriela Crispim; de Miranda, Gustavo Cabral; da Fonseca, Dennyson Leandro Mathias; Freire, Paula Paccielli; Hackel, Alexander M; Grasshoff, Hanna; Stähle, Anja; Müller, Antje; Dechend, Ralf; Yu, Xinhua; Petersen, Frank; Sotzny, Franziska; Sakmar, Thomas P; Ochs, Hans D; Schulze-Forster, Kai; Heidecke, Harald; Scheibenbogen, Carmen; Shoenfeld, Yehuda; Riemekasten, Gabriela.

In: AUTOIMMUN REV, Vol. 22, No. 5, 05.2023, p. 103310.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Cabral-Marques, O, Moll, G, Catar, R, Preuß, B, Bankamp, L, Pecher, A-C, Henes, J, Klein, R, Kamalanathan, AS, Akbarzadeh, R, van Oostveen, W, Hohberger, B, Endres, M, Koolmoes, B, Levarht, N, Postma, R, van Duinen, V, van Zonneveld, AJ, de Vries-Bouwstra, J, Fehres, C, Tran, F, do Vale, FYN, da Silva Souza, KB, Filgueiras, IS, Schimke, LF, Baiocchi, GC, de Miranda, GC, da Fonseca, DLM, Freire, PP, Hackel, AM, Grasshoff, H, Stähle, A, Müller, A, Dechend, R, Yu, X, Petersen, F, Sotzny, F, Sakmar, TP, Ochs, HD, Schulze-Forster, K, Heidecke, H, Scheibenbogen, C, Shoenfeld, Y & Riemekasten, G 2023, 'Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium', AUTOIMMUN REV, vol. 22, no. 5, pp. 103310. https://doi.org/10.1016/j.autrev.2023.103310

APA

Cabral-Marques, O., Moll, G., Catar, R., Preuß, B., Bankamp, L., Pecher, A-C., Henes, J., Klein, R., Kamalanathan, A. S., Akbarzadeh, R., van Oostveen, W., Hohberger, B., Endres, M., Koolmoes, B., Levarht, N., Postma, R., van Duinen, V., van Zonneveld, A. J., de Vries-Bouwstra, J., ... Riemekasten, G. (2023). Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. AUTOIMMUN REV, 22(5), 103310. https://doi.org/10.1016/j.autrev.2023.103310

Vancouver

Cabral-Marques O, Moll G, Catar R, Preuß B, Bankamp L, Pecher A-C et al. Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. AUTOIMMUN REV. 2023 May;22(5):103310. https://doi.org/10.1016/j.autrev.2023.103310

Bibtex

@article{2e8782e4f1d4411488520122020ed279,
title = "Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium",
abstract = "G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in L{\"u}beck, Germany, 15-16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.",
author = "Ot{\'a}vio Cabral-Marques and Guido Moll and Rusan Catar and Beate Preu{\ss} and Lukas Bankamp and Ann-Christin Pecher and Joerg Henes and Reinhild Klein and Kamalanathan, {A S} and Reza Akbarzadeh and {van Oostveen}, Wieke and Bettina Hohberger and Matthias Endres and Bryan Koolmoes and Nivine Levarht and Rudmer Postma and {van Duinen}, Vincent and {van Zonneveld}, {Anton Jan} and {de Vries-Bouwstra}, Jeska and Cynthia Fehres and Florian Tran and {do Vale}, {Fernando Yuri Nery} and {da Silva Souza}, {Kamilla Batista} and Filgueiras, {Igor Salerno} and Schimke, {Lena F} and Baiocchi, {Gabriela Crispim} and {de Miranda}, {Gustavo Cabral} and {da Fonseca}, {Dennyson Leandro Mathias} and Freire, {Paula Paccielli} and Hackel, {Alexander M} and Hanna Grasshoff and Anja St{\"a}hle and Antje M{\"u}ller and Ralf Dechend and Xinhua Yu and Frank Petersen and Franziska Sotzny and Sakmar, {Thomas P} and Ochs, {Hans D} and Kai Schulze-Forster and Harald Heidecke and Carmen Scheibenbogen and Yehuda Shoenfeld and Gabriela Riemekasten",
note = "Copyright {\textcopyright} 2023. Published by Elsevier B.V.",
year = "2023",
month = may,
doi = "10.1016/j.autrev.2023.103310",
language = "English",
volume = "22",
pages = "103310",
journal = "AUTOIMMUN REV",
issn = "1568-9972",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

AU - Cabral-Marques, Otávio

AU - Moll, Guido

AU - Catar, Rusan

AU - Preuß, Beate

AU - Bankamp, Lukas

AU - Pecher, Ann-Christin

AU - Henes, Joerg

AU - Klein, Reinhild

AU - Kamalanathan, A S

AU - Akbarzadeh, Reza

AU - van Oostveen, Wieke

AU - Hohberger, Bettina

AU - Endres, Matthias

AU - Koolmoes, Bryan

AU - Levarht, Nivine

AU - Postma, Rudmer

AU - van Duinen, Vincent

AU - van Zonneveld, Anton Jan

AU - de Vries-Bouwstra, Jeska

AU - Fehres, Cynthia

AU - Tran, Florian

AU - do Vale, Fernando Yuri Nery

AU - da Silva Souza, Kamilla Batista

AU - Filgueiras, Igor Salerno

AU - Schimke, Lena F

AU - Baiocchi, Gabriela Crispim

AU - de Miranda, Gustavo Cabral

AU - da Fonseca, Dennyson Leandro Mathias

AU - Freire, Paula Paccielli

AU - Hackel, Alexander M

AU - Grasshoff, Hanna

AU - Stähle, Anja

AU - Müller, Antje

AU - Dechend, Ralf

AU - Yu, Xinhua

AU - Petersen, Frank

AU - Sotzny, Franziska

AU - Sakmar, Thomas P

AU - Ochs, Hans D

AU - Schulze-Forster, Kai

AU - Heidecke, Harald

AU - Scheibenbogen, Carmen

AU - Shoenfeld, Yehuda

AU - Riemekasten, Gabriela

N1 - Copyright © 2023. Published by Elsevier B.V.

PY - 2023/5

Y1 - 2023/5

N2 - G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15-16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.

AB - G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15-16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.

U2 - 10.1016/j.autrev.2023.103310

DO - 10.1016/j.autrev.2023.103310

M3 - SCORING: Review article

C2 - 36906052

VL - 22

SP - 103310

JO - AUTOIMMUN REV

JF - AUTOIMMUN REV

SN - 1568-9972

IS - 5

ER -